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Abstract The present study investigated when during ‘in vitro’
maturation macrophages (Mx) express membrane C1q (mC1q),
and whether cell activation affects expression and function of
mC1q. Although C1q mRNA was repeatedly detected in freshly
isolated monocytes using reverse transcriptase-polymerase chain
reaction, C1q protein was observed only in developing Mx from
day 1 to 4 on using immunodetection and flow cytometry.
However, the quantity of mC1q and other Mx membrane
proteins differed strikingly in cells from different donors.
We report here for the first time that CD14+ and CD143
mC1q-bearing Mx can develop, and that interferon-Q increases
mC1q display at the cell surface, and mC1q-mediated
phagocytosis. ß 2001 Published by Elsevier Science B.V. on
behalf of the Federation of European Biochemical Societies.
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1. Introduction
Cells of the monocytic lineage are distributed throughout
organisms and exhibit a high degree of heterogeneity, partic-
ularly in their mature forms, such as macrophages (Mx) and
dendritic cells [1^3]. Monocyte-derived cells, in particular
Mx, appear to be the principal site of biosynthesis of the
collagen-like complement protein C1q [4^7]. Mx release a
soluble form of C1q that has been found to be identical to
its serum counterpart which in turn constitutes the activator-
recognizing part of the ¢rst complement component, C1 [5,8^
10]. C1q is a glycoprotein of about 460 kDa comprising 18
polypeptide chains, six each of which are from three di¡erent
gene products [11]. The molecular structure and the biological
function(s) of soluble C1q have been described in detail else-
where [4,12^16].
Previously, we have identi¢ed C1q as a presumptive integral
membrane protein (mC1q) of Mx that (i) mediates endocy-
tosis and (ii) is released from the extracellular side of the
plasma membrane to generate the soluble form [5,10]. There-
fore, mC1q itself shares properties with other well established
cell surface markers of Mx, such as CD14 and CD16 of
which soluble forms also exist [17^19].
The purpose of the present study was to detect when the
expression of mC1q protein in developing Mx ensues and to
investigate whether or not activation of the cells in£uences
expression and function of mC1q. Therefore we analyzed
monocytes/Mx isolated from human blood throughout in vi-
tro di¡erentiation for C1q synthesis at both the mRNA and
protein level. C1q mRNA was often, but C1q protein never
detected in freshly isolated monocytes using reverse transcrip-
tase-polymerase chain reaction (RT-PCR) and enzyme-linked
immunosorbent assay (ELISA) or Western blot, respectively.
Considerable C1q protein synthesis and membrane expression
occurred in cultured monocytes/Mx. Flow cytometry demon-
strated that the amount of mC1q on the cell surface varied
strikingly in cells from di¡erent donors.
For comparison with mC1q, we monitored the cell surface
expression of two additional well established Mx markers,
namely CD14 and HLA-DR. CD14 is a glycosyl-phosphati-
dylinositol (GPI)-anchored Mx membrane glycoprotein of 55
kDa. It serves as a receptor for a complex composed of lipo-
polysaccharide (LPS) and LPS-binding protein [17,20]. In ad-
dition, CD14 has been reported to mediate the phagocytosis
of infectious agents, such as Mycobacterium tuberculosis [21],
and apoptotic cells [22]. Furthermore, it is released from the
cell membrane by enzymatic cleavage of the GPI anchor or its
protein domain [17]. HLA-DR is a heterodimeric major his-
tocompatibility complex (MHC) class II molecule and plays a
crucial role in antigen presentation. Its plasma membrane ex-
pression in monocytic cells is generally upregulated under the
in£uence of activating in£ammatory cytokines, such as inter-
feron (IFN)-Q [23].
In the course of our investigation we observed previously
unknown CD14-positive and CD14-negative subpopulations
of mC1q-bearing Mx. Furthermore, we demonstrate for the
¢rst time that activation of Mx by IFN-Q signi¢cantly enhan-
ces expression of mC1q on the cell surface and mC1q-medi-
ated phagocytosis.
2. Materials and methods
2.1. Reagents
All chemicals, if not stated otherwise, were obtained in the highest
quality from Merck, Darmstadt, Germany. Acrylamide, bisacryl-
amide, 5-bromo-4-chloro-indolyl-phosphate, bovine serum albumin
(BSA), FITC, glycine, nitroblue tetrazolium, PMSF, SDS, SDS 7B
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molecular mass marker kit, Tris-base and Tween 20 were purchased
from Sigma Chemie GmbH, Deisenhofen, Germany.
2.2. Cells
The preparation of human monocytes and monocyte-derived Mx
was performed as previously described [5] with minor modi¢cations.
In brief, adherent monocytes were cultured for 8 days or indicated
time periods in RPMI 1640 containing 25 mM HEPES, 2 mM gluta-
mine (RPMI/HEPES; all Gibco BRL) and 10% either of human AB
serum (ABS) or fetal calf serum (FCS) (PAA Laboratories GmbH,
Coelbe, Germany). In some experiments on the ¢fth day in culture,
the medium including serum was exchanged for serum-free CG me-
dium (Vitromex GmbH, Vilshofen, Germany) with or without indi-
cated amounts of recombinant human IFN-Q (Genzyme Corporation,
Cambridge, MA, USA).
2.3. RNA isolation, cDNA synthesis and RT-PCR
RNA from freshly isolated or cultured monocytes/Mx was isolated
according to the method of Chomczynski and Sacchi [24]. The ¢nal
RNA concentration was estimated by spectrophotometry. First-strand
cDNA synthesis was accomplished as previously described [25] using a
Bioblock heater (Barnstead/Thermolyne, Dubuque, IA, USA). Table
1 lists the primers used for PCR in this study for ampli¢cation of
speci¢c cDNA templates, the applied annealing temperatures, the size
of the respective PCR product, the restriction endonucleases used for
speci¢c cleavage, and the size of the cleavage products. The forward
and reverse primers for ampli¢cation of each C1q chain react with
sequence regions in the ¢rst and second exon, respectively. Therefore,
these primers di¡erentiate between PCR products originating from
cDNA and genomic DNA. Ampli¢cation products of the latter are
about 1300, 1500 and more than 2000 bp in size for A-, B-, and C-
chains, respectively. Each reaction mixture included in a total volume
of 50 Wl 40.5 Wl H2O, 5 Wl 10U PCR bu¡er (500 mM KCl, 100 mM
Tris, 15 mM MgCl2, 0.1% gelatin, pH 8.3), 1 Wl dNTP (10 mM each;
Appligene Oncor, Heidelberg, Germany), 1 Wl of each primer (20
pmol ¢nal concentration; custom-built by Gibco BRL), 1 Wl cDNA
(equivalent to 300 ng of total RNA), 0.5 Wl Taq polymerase (5 U/ml).
The integrity of each cDNA sample was assessed by a PCR employing
primers speci¢c for human L-actin under the following conditions:
initial denaturation at 94‡C for 3 min followed by 33 cycles of (i)
45 s at 94‡C for denaturation, (ii) 45 s at 60‡C allowing annealing,
(iii) 1 min at 72‡C for extension and, at the end, another 5 min at
72‡C. For ampli¢cation of the C1q A-, B-, and C-chains the same
temperature pro¢le was applied except that the annealing tempera-
tures were changed according to the values listed in Table 1 and 35
cycles were performed. In each PCR run, genomic DNA (prepared as
described previously [26]) and cDNA of 8 day old Mx served as a
positive control. Reaction mixtures lacking either cDNA or one of the
primers provided the negative controls. A Hybaid Omnigene TR3
SM1 thermocycler (MWG Biotech, Ebersheim, Germany) was em-
ployed for all ampli¢cations. The PCR mixtures were run on ethidium
bromide-stained agarose gels. In order to check the speci¢city of the
PCR, ampli¢cation products of representative samples were extracted
from the agarose gel, precipitated with ethanol and digested with one
of the endonucleases listed in Table 1 (all purchased from New Eng-
land Biolabs GmbH, Schwalbach, Germany) according to the suppli-
er’s instructions.
2.4. Preparation of cell lysates
1^2U107 cells were lysed in 1 ml phosphate-bu¡ered saline contain-
ing 1 mM PMSF, 5 mM iodoacetamide, 5 mM EDTA, 10 mM so-
dium azide and 0.5% NP40 for 30 min at 4‡C as described previously
[5].
2.5. A⁄nity adsorption and immunoprecipitation
Mx lysates were sequentially incubated with immobilized BSA (10
mg/ml; BSA-S4B) and anti-huC1q monoclonal antibody (mAb)
242G3 (0.5 mg/ml; murine anti-huC1q-S4B) coupled to CNBr-acti-
vated Sepharose (S4B; Pharmacia Biotech AB, Uppsala, Sweden).
Precipitated proteins were eluted with SDS sample bu¡er [27], ana-
lyzed by SDS^PAGE and immunoblotting as detailed earlier [5,10].
2.6. Quantitation of C1q
The quantity of Mx C1q in cell lysates was assessed in a sandwich
ELISA. Anti-huC1q mAb 242G3 was used for detection and a goat
anti-huC1q IgG (prepared in our laboratory according to standard
procedures) served as the capture antibody (Ab) [28]. Serial dilutions
of puri¢ed human serum C1q in cell lysis bu¡er provided the standard
and bu¡er controls without C1q were included in each assay.
2.7. Flow cytometry
Flow cytometric analysis of cell surface molecules and phagocytosis
was accomplished as previously reported [5]. The analyzed proteins
and the employed mAbs were: mC1q: 242G3 (murIgG1; [29]), CD14:
12C3 (murIgM; Boehringer Mannheim, Mannheim, Germany), HLA-
DR: L243 (murIgG2a; ATCC, Rockville, MD, USA). The respective
isotype controls served: murIgG1: MOPC-21, murIgG2a: UPC-10,
murIgM: MOPC-104E (all Sigma). The incubation step with the sec-
ondary Ab, a FITC-conjugated goat anti-murIgG/IgM F(abP)2 frag-
ment (Dianova, Hamburg, Germany), was omitted, if the primary Ab
was conjugated to R-phycoerythrin. When cells of a donor were an-
alyzed two or three times at a given day for reproducibility reasons,
very similar results were obtained (data not shown).
For additive £uorescence measurements of C1q and CD14, cells
were in a ¢rst step incubated with the primary mAb directed against
one membrane molecule (anti-C1q or anti-CD14) or the respective
isotype control (murIgG1 or murIgM). In a second step, the cells
received the primary mAb recognizing the second antigen (anti-
CD14 or anti-C1q) or its respective isotype control (murIgM or mur-
IgG1) subsequent to one washing step. Therefore, the following sam-
ples were obtained: Mx incubated with (i) murIgG1 and murIgM, (ii)
anti-C1q and murIgM, (iii) murIgG1 and anti-CD14, and (iv) anti-
C1q and anti-CD14. The mAbs are given in the order of use. In all
experiments a set of samples was prepared with the inverse sequence
Table 1
RT-PCR of C1q A-, B-, and C-chains
Sample Primer Annealing
temperaturea (‡C)
Size of PCR
product (bp)
Speci¢city checkb
Sequence 5PC3P Enzyme Products (bp)
L-Actin for. ATTTGCGGTGGACGATGGAGGGGC
rev. GGCATCGTCACCAACTGGGACGAC 60 920 ND
C1q A for. ATGGTGACCGAGGACTTGTG
rev. GTCCTTGATGTTTCCTGGGC 62 276 BsaWI 158+119
C1q B for. ACCCCAGGGATAAAAGGAGAG
rev. (1) GGCAGAGAAGGCGATTTTCTG 60 216
rev. (2) AGGTCAGGCCTCCATATCTG 60 602 PstI 511+91
XhoI 364+238
C1q C for. AAGGATGGGTACGACGGACTG
rev. (1) TTTCTGCTTGTATCTGCCCTC 65 213 SmaI 153+59
rev. (2) GGTGGGTCCTAGCAGAAGCTGAGGAGGTGGAAGGCc 65 663 BclI 391+271
aAnnealing temperature used in the PCR reaction.
bThe PCR products were cut o¡ the agarose gel, extracted, precipitated with ethanol and ¢nally resuspended in the reaction bu¡er of the re-
spective enzyme.
cThis primer contains 35 nucleotides.
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of mAb application. Bound mAbs were detected with the FITC-la-
beled F(abP)2 fragment mentioned above. The respective equivalent
samples di¡ered on average by 1.6% with respect to the percentage
of positive cells.
For a phagocytosis assay, each 5U104 Mx were incubated with
FITC-labeled Pansorbin0 bacteria (¢xed Staphylococcus aureus ;
PsbFITC) which had been coated before with the anti-huC1q mAb
242G3 or murIgG1 as an isotype control (20, 30, 40 or 50 Wg per
1U108 PsbFITC) in a total volume of 200 Wl for 30 min at 37‡C. Cells
were then chilled on ice and washed three times with ice-cold bu¡er
prior to immediate analysis by £ow cytometry. To estimate the
amount of ingested bacteria, trypan blue solution was added to a ¢nal
concentration of 1 mg/ml to quench the £uorescence of adherent
extracellular bacteria [5].
Flow cytometry analysis was performed using an EPICS Pro¢le II,
the EPICS Pro¢le and ELITE software packages (versions 2.26 and
3.0, respectively; Coulter Electronics GmbH, Krefeld, Germany). Mx
were gated according to their characteristic forward and sideward
light scattering properties [30]. The £uorescence data are expressed
in relative mean £uorescence intensity (rMFI) which was calculated
according to Te Velde et al. [31]:
rMFI 
MFI of Mx incubated with specific mAb or coated PsbFITC
MFI of Mx incubated with isotype control mAb or coated ctl PsbFITC
3. Results
3.1. Expression of C1q in monocytes/Mx throughout in vitro
di¡erentiation
Monocytes were isolated from blood of healthy donors and
used either directly or following culture for indicated periods
of time. In order to obtain su⁄cient amounts of RNA and/or
cellular protein from all samples collected, cells of two to four
donors were processed in parallel and pooled immediately
prior to RNA isolation or protein solubilization.
3.1.1. RT-PCR of C1q A-, B-, and C-chains. RT-PCR of
the three chains of C1q and L-actin was performed as men-
tioned in Section 2 and the results are shown in Fig. 1. Where-
as mRNA of all three C1q chains was always detected in
cultured monocytes/Mx, freshly isolated monocytes displayed
only two out of three times (six samples) detectable amounts
of the respective transcripts (Fig. 1, compare lanes 1 and 9).
For B- and C-chains two di¡erent reverse primers were em-
ployed, each of which induced a reaction product of the ex-
pected, speci¢c size (Table 1). Fig. 1 presents the RT-PCR
products obtained with the reverse primer ‘1’. Substitution
of genomic DNA for cDNA induced for each C1q chain a
product of greater size, indicating the presence of the respec-
tive intron. Enzymatic digestion of the RT-PCR bands yielded
the calculated cleavage products listed in Table 1, and pro-
vided additional evidence of speci¢city (data not shown).
3.1.2. Determination by ELISA and immunoprecipitation of
Mx C1q in cell lysates. Cell lysates of freshly isolated mono-
cytes or cultured monocytes/Mx were investigated either em-
ploying an ELISA system for quantitative estimation of C1q
or by immunoprecipitation and immunoblotting to visualize
Mx C1q. Fig. 2A shows that the quantity of cellular C1q
mostly increased throughout the course of culture but also
considerably varied between lysates obtained from di¡erent
cell preparations and thus donor pools. Furthermore, C1q
was ¢rst detected in cultured monocytes/Mx on day 1, 2 or
3 by use of the ELISA (Fig. 2A, lysates 5 and 6, 4, 2 and 3,
respectively). The Mx C1q displayed in Fig. 2B was precipi-
tated from the respective samples of ‘cell lysate 1’ depicted in
Fig. 2A. The immunoblot shows that C1q is present in the
Fig. 1. RT-PCR of C1q A-, B-, and C-chains. Images of ethidium bromide-stained agarose gels displaying RT-PCR products of the indicated
C1q chain (A^C) and L-actin. The sizes of the RT-PCR products are indicated (compare Table 1). In case of B- and C-chains, products are
shown that were obtained using the respective reverse primer ‘1’. RNA was prepared of freshly isolated and 1^8 days cultured monocytes/Mx
and RT-PCR accomplished as described in Section 2. Samples shown in tracks 1^7 and 9^12 represent pools of cells obtained from four and
two donors, respectively. Tracks 8 and 13 represent reaction mixtures in which cDNA was omitted.
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cells from day 4 onwards, but not immediately after separa-
tion from blood and, in this case, on day 2 of culture. The
results obtained using the ELISA and the combination of
immunoprecipitation with Western blotting con¢rm each oth-
er.
3.2. Flow cytometric analysis of monocyte/Mx cell surface
markers
In order to investigate the development and the pheno-
type(s) of the C1q-synthesizing Mx population derived from
a single individual, monocytic cells of di¡erent donors were
separately analyzed throughout in vitro culture by £ow cyto-
metry for cell surface expression of C1q and CD14. Fig. 3
shows that mC1q is hardly, if at all, discernible in freshly
isolated monocytes (day 0; donors 1^3, 5 and 6 about 2%
and donor 4 5.6% positive cells) but clearly occurs in cultured
cells (donors 1^11). A major peak of mC1q appearance on the
cell surface was observed on day 8 of culture (donors 1^3 and
7^11). However, monocytes/Mx of some donors remained
virtually negative for mC1q throughout day 2 and displayed
only a weakly positive signal even on day 8 of culture (donors
5 and 6).
Cell surface expression of CD14 was always strong at the
beginning and, as observed in cells of donors 1, 2, 4 and 5, for
up to day 10 throughout in vitro culture. Sometimes however,
the percentage of CD14-positive monocytes/Mx clearly de-
creased in the course of the culture (donors 3 and 6).
Monocytes develop into Mx when cultured for about 8 days
in the presence of serum, which can be either FCS or ABS
[32,33]. Therefore, we investigated Mx following culture in
the presence of ABS or FCS for the appearance of mC1q,
CD14, and HLA-DR on their cell surface. HLA-DR was
analyzed as an additional Mx marker, as an increase of its
expression indicates activation [23]. Fig. 4 summarizes the
results and shows that the expression of all three plasma
membrane molecules varies considerably between Mx from
di¡erent donors (n = 27). The diversity in the cell surface phe-
notype is demonstrated by the di¡erence between the percent-
age of positive cells and the rMFI as a measure of the mol-
ecule number on the cell surface. When monocytes/Mx were
cultured in parallel in media containing ABS (MxABS) or FCS
(MxFCS), the expression of mC1q and CD14 exhibited, on
average, no signi¢cant di¡erences between the respective cell
populations. In contrast, the expression of HLA-DR was sig-
ni¢cantly higher in MxABS than in MxFCS both in terms of
Fig. 2. Antigenic detection of Mx C1q by ELISA (A) and immuno-
precipitation and immunoblotting (B). Lysates were prepared of
freshly isolated (day 0) and 1 and up to 10 days cultured mono-
cytes/Mx and subsequently subjected to analysis by either ELISA
or immunoprecipitation and blotting as detailed in Section 2.
Amounts of C1q per 107 cells depicted in (A) represent cell pools
prepared from monocytes/Mx of four (lysates 1^3), three (lysates 5
and 6), and two (lysate 4) donors. Mx C1q displayed in (B) was
precipitated from lysate 1. C1q A-, B-, and C-chains were separated
by SDS^PAGE (12.5/1.2% acrylamide/bisacrylamide) prior to immu-
noblotting and are indicated on the right-hand side. ‘Ctl’ indicates a
control sample eluted with SDS sample bu¡er from an aliquot of
the immobilized anti-huC1q mAb that was not incubated with a cell
lysate.
Fig. 3. Flow cytometric analysis of cell surface expression of mC1q
and CD14 (top to bottom) in monocytes/Mx throughout in vitro
culture/di¡erentiation. Each curve in a graph represents cell samples
of an individual blood donation (1^11) assessed at the indicated
time. Identical donor numbers in both graphs indicate cells originat-
ing from the same individual.
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positive cells and antigen density (rMFI). However, when
pairs of MxABS and MxFCS of eight donors were investigated,
we found that in 50% of the matched samples the level of
mC1q expression was signi¢cantly higher in MxABS compared
to MxFCS. The opposite occurred in the remaining 50% (Fig.
5). Interestingly, the mean rMFI values for mC1q of MxFCS
were almost identical in both groups. Although, the variability
was much higher in the group in which the MxABS expressed
less mC1q compared with their MxFCS counterparts, and the
di¡erence did not reach statistical signi¢cance.
In the cells of the majority of the donors the percentage of
CD14-positive Mx was greater than that of C1q-positive cells
(19 of 27 samples, Fig. 4). However, in several cases the op-
posite was observed (eight of 27 samples shown in Fig. 4),
suggesting the existence of a C1q-positive but CD14-negative
Fig. 4. Flow cytometric analysis of cell surface antigens of Mx on
day 8 of culture. Cells obtained from 27 healthy donors were cul-
tured in medium containing ABS (MxABS) or FCS (MxFCS). Aver-
ages of rMFIs and percentages of positive cells are given. Note that
the bars in the columns indicate the range (highest and lowest) of
the respective values observed for a given antigen. A two samples
for means t-test assuming an unidirectional hypothesis was per-
formed for statistical analysis.
Fig. 5. Flow cytometric assessment of mC1q in matched pairs of
MxABS and MxFCS from eight donors. The rMFIs þ S.D. are given.
Statistical analysis applied a paired two samples for means t-test as-
suming an unidirectional hypothesis. MC1q expression of MxABS
was analyzed in comparison to MxFCS in both groups (n = 4, re-
spectively).
Fig. 6. Assessment of CD14-positive and CD14-negative mC1q-bear-
ing Mx subpopulations by £ow cytometry. LSS: logarithmic side
scatter; LFL1: logarithmic £uorescence 1 (FITC). (A) Gating of
monocyte-derived Mx on day 8 of culture based on forward and
sideward scatter properties (cells shown here were cultured in me-
dium containing FCS). (B) Additive £uorescence measurement was
performed after sequential incubations of the cells with the two spe-
ci¢c Abs (anti-huC1q mAb and anti-CD14 mAb) or the respective
isotype controls (murIgG1 and murIgM) or combinations of these
as indicated on the right. The order in which the mAbs are given
represents the sequence of application before the ¢nal staining with
the FITC-labeled secondary Ab. The cytograms in the left column
display cell size and £uorescence. Note the di¡erence in size of the
CD14-negative and CD14-positive cells (second cytogram from the
bottom) and the shift in £uorescence intensity of the CD14-negative
cells when stained with the anti-huC1q mAb (bottom). One repre-
sentative out of nine samples is shown.
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Mx subpopulation. Assessment of CD14-positive and CD14-
negative mC1q-bearing Mx was performed in additional sam-
ples by additive £uorescence measurement. Fig. 6 shows a
representative example. Fig. 6A displays both the forward
and logarithmic side scatter properties of a typical Mx pop-
ulation on day 8 of culture. Fig. 6B demonstrates that a sub-
population of these Mx staining negative for CD14 (see cyto-
gram and frequency histogram labeled: murIgG1+aCD14)
shifts into the gate of positive cells, if incubated with the
anti-huC1q mAb. Table 2 summarizes the assessment of the
CD14-negative and mC1q-positive Mx subpopulation in nine
samples derived from ¢ve donors. In three out of four pairs of
MxABS and MxFCS, the number of C1q-positive/CD14-nega-
tive Mx was signi¢cantly higher in the MxABS. In terms of
percentage, the CD14-negative subpopulation was always
smaller than the CD14-positive counterpart, whereas with re-
spect to cell size, the opposite was observed (Fig. 6B). When
expressed in arbitrary forward scatter units (FSU), the CD14-
positive and CD14-negative Mx had an average size of 24 þ 3
and 39 þ 3.1, respectively. The whole Mx population dis-
played an average size of 27.8 þ 1.5 (FSU þ S.D. from six de-
terminations).
3.3. In£uence of IFN-Q on mC1q and mC1q-dependent
phagocytosis
Since mC1q-bearing Mx originating from di¡erent donors
exhibited a striking diversity, we wondered whether or not this
could be a consequence of activation and thus, if cytokine
stimulation of the cells a¡ects mC1q expression. Monocytes/
Mx were cultured for 8 days but between day 5 and 8 were in
the presence or absence of the indicated amounts of recombi-
nant human IFN-Q. Subsequently, the cells were assayed by
£ow cytometry for the cell surface expression of mC1q, CD14
and HLA-DR and for their ability to perform mC1q-depen-
dent phagocytosis (Fig. 7 and Table 3). Expression of MHC
class II molecules generally increased when the Mx received
the stimulus. However, a signi¢cantly higher antigen density
Table 2
Percentages of MC1q/CD143 Mx : additive £uorescence measure-
ment
Donor MC1q/CD143 Mx (%)
Cell culture typea
MxABS MxFCS
1 25.0 36.9
2 15.8 20.0
3 1.5 15.6
4 ND 11.3
5 14.6 2.4
Additive £uorescence measurement was performed as described in
Section 2.
Within the bold samples, the di¡erence of the percentage of
MC1q/CD143 cells in MxABS and MxFCS is statistically signi¢-
cant (P6 0.04, paired two samples for means t-test).
aCells obtained from a donor were cultured in parallel in medium
containing ABS (MxABS) or FCS (MxFCS).
Fig. 7. In£uence of IFN-Q on the expression of mC1q, CD14 and
HLA-DR in Mx. Results of the £ow cytometric analysis on day 8
of culture. Cells were cultured in the presence of ABS until day 5.
The culture in the presence or absence of IFN-Q was performed in
serum-free CG medium from day 5 to 8.
Table 3
Flow cytometric assessment of mC1q-dependent phagocytosis by Mx : enhancing e¡ect of IFN-Q
Cell culture rMFI ( þ S.D.)
Type Additive Adherent and ingested coated PsbFITCa Ingested coated PsbFITCb
MxABS=CG none 2.25 ( þ 0.83)* 2.40 ( þ 1.19)**
IFN-Q 3.29 ( þ 0.81)* 3.14 ( þ 0.60)**
P6 0.009* (n = 9) P6 0.04** (n = 9)
Culture in the presence or absence of IFN-Q (1000 U/ml) was performed in CG medium from day 5 to 8 (MxABS=CG). The phagocytosis assay
was performed as described in Section 2 and the rMFI is given.
*, **: A paired two samples for means t-test was employed for statistical analysis of the di¡erences of the rMFI values observed for IFN-Q-
stimulated and untreated cells (nine pairs).
aAdherent, extracellular and ingested, coated PsbFITC (PsbFITC-KC1q mAb versus PsbFITC-murIgG1).
bIngested, coated PsbFITC, £uorescence of extracellular adherent, coated PsbFITC quenched with trypan blue solution (¢nal concentration
1 mg/ml).
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(represented by rMFI) occurred only under treatment with the
highest concentration of IFN-Q (1000 U/ml). Notably,
although the mean percentage of HLA-DR-positive cells in-
creased, the all over change was not signi¢cant. However, Fig.
7 shows that the expression of mC1q always increased under
the in£uence of IFN-Q. The improvement of the antigen den-
sity as indicated by the rMFI was always statistically signi¢-
cant, whereas the increase of the percentage of positive
cells was only signi¢cant if the cells had been treated with
1000 U/ml of IFN-Q.
In contrast to mC1q and HLA-DR protein, the expression
of CD14 on the plasma membrane remained basically un-
changed by IFN-Q.
The analysis of mC1q-mediated phagocytosis of IFN-Q-
treated and untreated cells is summarized in Table 3. The
results demonstrate that the £uorescence signals evoked by
the adherent and ingested FITC-labeled Pansorbin0 bacteria
(PsbFITC) and the ingested material alone are 2.25 and 2.40
times higher, respectively, if the PsbFITC had been coated with
the anti-huC1q mAb that links the particles to mC1q. The
£uorescence signals for this speci¢cally mC1q-dependent ad-
herence and uptake increased signi¢cantly, when the Mx were
stimulated with IFN-Q (P6 0.009 for adherent and ingested
PsbFITC, P6 0.04 for ingested particles, n = 9 sample pairs;
Table 3).
4. Discussion
Previously, we have shown that the collagen-like C1q mol-
ecule is a presumably integral membrane protein of Mx
[5,10]. The apparent lack of mC1q on monocytes, the precur-
sors of Mx, suggested that mC1q may be a marker of matur-
ing Mx [5]. In the present study, we investigated the expres-
sion of Mx C1q/mC1q on the mRNA and protein level
throughout in vitro di¡erentiation of Mx. Formation of a
functional C1q molecule appears to depend critically on the
production of three mRNA species and the simultaneous oc-
currence of the respective protein chains as concluded from
known C1q-de¢ciencies [26,34]. Therefore, we designed RT-
PCRs for detection of mRNA of all three C1q chains. Inter-
estingly, mRNA of C1q A-, B-, and C-chains was not only
detected in cultured cells but also in two out of three fresh
monocyte preparations (Fig. 1). In contrast, C1q protein was
never detected in lysates of freshly isolated monocytes by
ELISA and immunoprecipitation combined with Western
blotting. This result is in accordance with previous studies
performed in our laboratory [5,10,35] and by other investiga-
tors [36]. However, detectable expression of C1q protein/
mC1q ensued in 1^4 day old cultured monocyte-derived
Mx. This suggests that the three mRNAs for C1q could be
transcribed in advance of the onset of C1q protein synthesis.
Flow cytometry allows to study the expression of proteins
on the single-cell level and was used to investigate separately
mC1q expression in cells of individual donors.
This approach revealed in six of 11 cases some 2% C1q-
positive cells within the freshly isolated monocytes (Fig. 3;
MC1q, day 0). In the present study, all experiments were
performed in bu¡ers resembling physiological conditions,
and we and others have shown that monocytes show no spe-
ci¢c C1q-binding activity in bu¡ers of physiological ionic
strength [35,36]. Indeed, addition of soluble C1q to fresh
monocyte preparations did not increase the population of
C1q-positive cells (data not shown, but see [35]). Therefore,
the low number of C1q-positive cells could be explained by
the presence of some ‘contaminating’ cells, such as granulo-
cytes, which, in contrast to monocytes, bind serum C1q
[35,37]. However, it is also possible that some mature Mx
which other investigators have reported to be present in the
circulation [38] had been co-puri¢ed with monocytes. C1q
originating from a small number of mature Mx or C1q-bind-
ing granulocytes would probably not be detected by ELISA or
immunoblotting due to its low concentration. However, a low
number of mC1q producing circulating Mx could account for
the C1q mRNA detected by RT-PCR in freshly isolated
monocytes.
Assessment of mC1q in cell lysates and £ow cytometry
demonstrated that the expression occurred and increased
throughout Mx maturation with striking di¡erences between
cells from di¡erent donors (Figs. 2 and 3). Under our exper-
imental conditions, the quantity of cellular C1q was the high-
est at days 4 or 5 (Fig. 2: lysates 1 and 4) or increased
throughout culture until termination of the experiment (Fig.
2: lysates 2, 3, 5 and 6, respectively). The percentage of Mx
exhibiting mC1q on the cell surface was maximal on day 8 of
culture in eight out of 11 samples (Fig. 3). An earlier report
by Kaplan and Gaudernack [32] that most cultured mono-
cytes develop within 8 days into mature Mx may explain
our observation: at day 8 of culture most cells may have
reached the stage of mature Mx that express mC1q.
Interestingly, human ABS, when compared to FCS, ap-
peared to exert an either enhancing or suppressing e¡ect on
mC1q expression in cells from di¡erent donors (Fig. 5). This
suggests that human serum components indeed regulate C1q
production. However, the reason(s) for this diverging reaction
of monocytes to human serum which imply a predisposition
of the donor remain to be elucidated.
Taken together, our results demonstrate that synthesis of
mC1q in monocyte-derived Mx is developmentally regulated.
Therefore, mC1q shares features with other cell surface mol-
ecules of Mx, such as CD16 [39].
In the case of CD14, the cells maintained a strong cell sur-
face expression or displayed a reduction in the course of the
culture (Figs. 3 and 4), both of which are in good accordance
with reports of other groups (reviewed in [17]). However,
closer analysis of Mx populations by additive £uorescence
measurement showed for the ¢rst time the existence of distinct
CD14-positive and CD14-negative mC1q-expressing Mx sub-
populations. The two cell populations di¡er in relative num-
bers and morphological measures: CD14-negative cells are
usually smaller in terms of counts but greater in terms of
cell size. Interestingly, these subpopulations appeared only
in cells from some donors, but if so then in both MxABS
and MxFCS, and without the addition of any exogenous stim-
ulus. This suggests that occurrence of CD14-positive or
CD14-negative mC1q-expressing Mx is determined indepen-
dently of the culture media, but rather by a predisposition of
the donor. At presence the factor(s) which drive the develop-
ment of the subpopulations remain to be elucidated and the
physiological function of the observed Mx subpopulations
will be subject of future investigations.
Monocytes develop into Mx regardless of the presence of
ABS or FCS in the culture medium [32]. However, di¡erences
occurred in the present study between MxABS and MxFCS not
only in the percentage of positive cells and the amount of
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mC1q (see above), but also with respect to HLA-DR mole-
cules residing on the membrane (Fig. 4). The relatively higher
expression of the MHC class II molecules in MxABS could be
due to the presence of stimulating factors in ABS which FCS
might lack and/or species di¡erences.
We also wondered whether or not activation of the Mx
in£uences the appearance and function of mC1q. IFN-Q is a
stimulus of Mx which has been reported to increase the ex-
pression of MHC class II molecules [23]. Interestingly, a sig-
ni¢cant enhancement of HLA-DR expression was only de-
tected when we applied 1000 U/ml of IFN-Q (Fig. 7). Since
MxABS showed a strong and signi¢cantly higher MHC class
II molecule expression than MxFCS (Fig. 4) even without
addition of IFN-Q, a further massive increase in the number
of positive cells could not be expected. But a signi¢cant im-
provement of the antigen density on the cell surface also re-
quired a high dose of IFN-Q. However, our results demon-
strate for the ¢rst time that activation of Mx in£uences
signi¢cantly the expression and function of mC1q as IFN-Q
increased the expression of mC1q (Fig. 7) and enhanced the
mC1q-mediated phagocytosis (Table 3). Our ¢nding and the
observation by others that C1q-de¢cient mice show a reduced
capacity to produce IFN-Q [40] suggest that C1q and IFN-Q
are engaged in a mutual immunoregulatory mechanism. In
contrast, expression of CD14 was not signi¢cantly a¡ected
by IFN-Q. This and the CD143/mC1q Mx indicate that
CD14 is independently regulated from mC1q.
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